Curcumin Temporarily Slows Pancreatic Cancer
    Small Number With Advanced Disease Respond  

    By Darcy De Leon

    Curcumin, a compound in the spice turmeric, temporarily stopped advanced pancreatic cancer growth in
    two patients and substantially reduced the size of a tumor in another patient, according to a small study
    published July 15 in the journal Clinical Cancer Research.

    Significance of results

    In the Phase II M. D. Anderson study of 25 patients, curcumin was given on its own without chemotherapy.  

    “The effects of curcumin were encouraging,” says the study’s principal investigator, Razelle Kurzrock, M.D.,
    chair of M. D. Anderson’s Department of Investigational Cancer Therapeutics (Phase I clinical trial
    program). “It showed activity in patients, and there were no side effects.”

    A concern before starting the study was that curcumin normally is poorly absorbed, meaning that only low
    levels get into the bloodstream after the capsule form has been taken by mouth.

    “Therefore, the fact that low levels of curcumin resulted in benefits in the study, even in a small number of
    patients, suggests that if we could find a better way to administer curcumin and get it to the tumor, we could
    see a greater response,” Kurzrock says.

    The fact that curcumin had any effect on patients with pancreatic cancer, which is difficult to treat
    successfully, is significant to Bharat Aggarwal, Ph.D., professor in the Department of Experimental
    Therapeutics.

    “The results are important,” says Aggarwal, a laboratory scientist who has studied curcumin as a potential
    cancer-fighting agent in cancer cells and mice for nearly 20 years.  

    Research methods

    Patients received 8 grams of curcumin by mouth every day for two months. Maintenance therapy was
    continued at the same dose and schedule until the disease progressed.

    Primary results

    Twenty-five patients were reported in the paper.

    Of those patients, curcumin resulted in:

    Prolonged stable disease: Two patients temporarily experienced no significant tumor growth; one for eight
    months and another patient for just over 2.5 years (an additional 12 months after the study was compiled
    for publication).  

    Tumor regression: One patient experienced a decrease in tumor size of 73%, although the tumor grew back
    soon afterward.

    “Interestingly, at the time of progression, the lesions that had shrunk remained small, but other lesions grew
    larger,” according to the study.

    “That suggests that a resistant clone of cancer cells emerged, which is a real problem in treating cancer,”
    Kurzrock says.

    In addition, no side effects were observed in patients.

    Background

    Curcumin is a substance that comes from the root-bearing Curcuma longa plant, a member of the ginger
    family. Curcumin is an ingredient in turmeric, a spice used in foods such as curry.

    Curcumin has been studied in numerous research studies and has been found to contain potential anti-
    tumor abilities.

    Curcumin is used in India as a:

    Food preservative
    Coloring agent for food and textiles  
    Spice (2% to 5% of turmeric is curcumin)
    Folk medicine to:
    Cleanse the body
    Heal wounds
    Prevent wrinkles
    Suppress inflammation
    Knowledge of curcumin’s anti-inflammatory properties and the growing realization that cancer can result
    from inflammation has spurred mounting interest in the spice, Aggarwal says.

    The study was conceived and developed through a collaboration among Kurzrock, who chairs a department
    devoted to studies with new drugs; James Abbruzzese, M.D., chair of M. D. Anderson's Department of
    Gastrointestinal Medical Oncology and an expert in pancreatic cancer; and Aggarwal.

    Their work demonstrated that in laboratory and animal studies, curcumin was especially potent against
    pancreatic cancer.

    What’s next?

    Researchers are seeking funding for additional clinical trials using curcumin.

    “We plan to study curcumin together with other anti-cancer drugs, since combined therapy is likely to
    enhance results,” Kurzrock says. “In addition, we are developing a liposomal form of curcumin (curcumin
    packed within a fat-type capsule) that can be taken orally and travel directly through the bloodstream.
    Hopefully, this form will improve the ability of curcumin to reach the tumor.”
HOME